vascular issues associated with bevacizumab
DESCRIPTION
Vascular issues associated with bevacizumab. Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer Center New York. Bevacizumab. Improved survival in first line metastatic colorectal cancer with chemotherapy - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/1.jpg)
Vascular issues associated with bevacizumab
Stuart M. Lichtman, MD, FACP
65+ Clinical Geriatric Program
Associate Attending
Memorial Sloan-Kettering Cancer Center
New York
![Page 2: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/2.jpg)
Bevacizumab
• Improved survival in first line metastatic colorectal cancer with chemotherapy
• Improved survival in previously treated metastatic colorectal cancer
• Improved survival in previously untreated nonsquamous nonsmall cell lung cancer
• Improved PFS in previously untreated metastatic breast cancer
![Page 3: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/3.jpg)
Bevacizumab
• In pivotal trial of metastatic colorectal cancer 3.3% vs. 1.0% (placebo) experienced arterial thrombotic event
• No increased incidence of venous thromboembolism
Scappaticci 2007
![Page 4: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/4.jpg)
ATE
• angina pectoris, arterial thrombosis, cerebral infarct, cerebral ischemia, cerebrovascular accident, myocardial infarction, and myocardial ischemia.
![Page 5: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/5.jpg)
ExclusionsWithin 1 year of study entry
1. un -controlled hypertension
2. myocardial infarction
3. unstable angina
4. congestive heart failure NYHA class II or higher
5. serious cardiac arrhythmia requiring medication
6. grade 2 or higher peripheral vascular disease
any history of
1. stroke
2. chronic daily treatment with aspirin (>325 mg/day)
3. nonsteroidal anti-inflammatory medications at doses known to inhibit platelet function
4. Current full-dose anticoagulation (within 10 days before treatment)
![Page 6: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/6.jpg)
ATE
Scappaticci 2007
![Page 7: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/7.jpg)
Patients
• 1745 patients– Colorectal cancer 69%– Breast cancer 25%– Non small cell lung 6%
– Fluoropyrimidine based therapy 94%
– Bevacizumab• 5 mg/kg/week 31%• 2.5 mg/kg/week 69%
Scappaticci 2007
![Page 8: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/8.jpg)
ATE
Overall• Difference in ATE
– 3.8% vs. 1.7%
• Rate per 100 person years– 5.5 vs. 3.1
• ATE causing death– 0.62% vs. 0.26%
• VTE– 9.97% vs. 9.85%
Scappaticci 2007
![Page 9: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/9.jpg)
Time to First ATE
Scappaticci 2007
![Page 10: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/10.jpg)
Risk Factors
• Evaluated:– Exposure to bevacizumab– Age >65 years– Hypertension at baseline– History of ATE– History of atherosclerosis– History of myocardial infarction
Scappaticci 2007
![Page 11: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/11.jpg)
Risk Factors
• Evaluated:– Exposure to bevacizumab (P=0.04)– Age >65 years (P=0.01)– Hypertension at baseline– History of ATE (P<0.001)– History of atherosclerosis– History of myocardial infarction
Scappaticci 2007
![Page 12: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/12.jpg)
Risk Factors
Scappaticci 2007
![Page 13: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/13.jpg)
Elderly Patients and the Risk ofArterial Thromboembolic Events
(ATEs)Percent
Chemotherapy
Alone
(n=782)
bevacizumab
+ Chemotherapy
(n=963)
ATEs (overall)* 1.7 3.8
<65 years 1.4 2.1
65 years 2.5 7.1
Scappaticci 2007
![Page 14: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/14.jpg)
Elderly Patients and the Risk ofArterial Thromboembolic Events
(ATEs)Percent
Chemotherapy
Alone
(n=782)
bevacizumab
+ Chemotherapy
(n=963)
ATEs (overall)* 1.7 3.8
<65 years 1.4 2.1
65 years 2.5 7.1
Scappaticci 2007
![Page 15: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/15.jpg)
ATE Incidence by Risk Group
% of ATE
Baseline risk factor
(% of population)
Control
(n/N)
BV
(n/N)
All patients
(100)
1.7
(13/782)
3.8
(37/963)
None
(63)
1.0
(5/490)
1.8
(11/602)
Age >65 years*
(35)
2.5
(7/279)
7.1
(24/339)
History of ATEs*
(8.5)
3.4
(2/59)
15.7
(14/89)
Both
(6.5)
2.2
(1/46)
17.9
(12/67)
*not mutually exclusiveScappaticci 2007
![Page 16: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/16.jpg)
ATE Incidence by Risk Group
% of ATE
Baseline risk factor
(% of population)
Control
(n/N)
BV
(n/N)
All patients
(100)
1.7
(13/782)
3.8
(37/963)
None
(63)
1.0
(5/490)
1.8
(11/602)
Age >65 years*
(35)
2.5
(7/279)
7.1
(24/339)
History of ATEs*
(8.5)
3.4
(2/59)
15.7
(14/89)
Both
(6.5)
2.2
(1/46)
17.9
(12/67)
*not mutually exclusiveScappaticci 2007
![Page 17: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/17.jpg)
ATE Incidence by Risk Group
% of ATE
Baseline risk factor
(% of population)
Control
(n/N)
BV
(n/N)
All patients
(100)
1.7
(13/782)
3.8
(37/963)
None
(63)
1.0
(5/490)
1.8
(11/602)
Age >65 years*
(35)
2.5
(7/279)
7.1
(24/339)
History of ATEs*
(8.5)
3.4
(2/59)
15.7
(14/89)
Both
(6.5)
2.2
(1/46)
17.9
(12/67)
*not mutually exclusiveScappaticci 2007
![Page 18: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/18.jpg)
ATE Incidence by Risk Group
% of ATE
Baseline risk factor
(% of population)
Control
(n/N)
BV
(n/N)
All patients
(100)
1.7
(13/782)
3.8
(37/963)
None
(63)
1.0
(5/490)
1.8
(11/602)
Age >65 years*
(35)
2.5
(7/279)
7.1
(24/339)
History of ATEs*
(8.5)
3.4
(2/59)
15.7
(14/89)
Both
(6.5)
2.2
(1/46)
17.9
(12/67)
*not mutually exclusiveScappaticci 2007
![Page 19: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/19.jpg)
Aspirin Use
• More common patients with history of ATE
• Aspirin use associated with increased risk of bleeding in both groups
• No difference between bevacizumab and control
• Data not adequate to comment on prophylaxis
Scappaticci 2007
![Page 20: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/20.jpg)
Risk-Benefit
Scappaticci 2007
![Page 21: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/21.jpg)
Lung CancerPaclitaxel/Carboplatin +/- bevacizumab
Ramalingam 2008
![Page 22: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/22.jpg)
Lung CancerPaclitaxel/Carboplatin +/- bevacizumab
• Elderly patients had higher incidence of grade 3 to 5 neutropenia, bleeding, and proteinuria with PCB compared with younger patients.
Conclusion
In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients.
Ramalingam 2008
![Page 23: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/23.jpg)
BevacizumabLong Term: BRITE
Observational Cohort
Safety Events Duration of exposure
<12 months; N=1396 >12 months; N=557
% %
Perforation 2.2 0.3
ATE 2.1 0.7
Gr 3-4 bleeding 2.6 0.7
New or increased HT 17.3 27.5
Median followup 20.8 months
ASCO 2008
![Page 24: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/24.jpg)
Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer
(mCRC): Results from the BRiTE Prospective Cohort Study
GI ASCO 2008
![Page 25: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/25.jpg)
Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil /leucovorin and oxaliplatin (mFOLFOX6) with or without bevacizumab in the adjuvant treatment of patients
with stage II/III colon cancer.
ASCO 2008
![Page 26: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/26.jpg)
Questions
• Is this risk applicable to general elderly population?
• What should be recommended to patients with increased comorbidity?
• What should be recommended to patients with more recent ATE?
• Were there functional consequences of ATE which affect QOL?/
![Page 27: Vascular issues associated with bevacizumab](https://reader035.vdocument.in/reader035/viewer/2022062422/56813025550346895d95ae1c/html5/thumbnails/27.jpg)
Conclusion
• Bevacizumab is an important component of therapy in various solid tumors
• Vascular complications of therapy is a well recognized entity
• Patient selection is critical to ensure safety with this palliative treatment